Abstract 702P
Background
Human leukocyte antigens (HLAs) are expressed in a variety of cells, including cancer cells and immune cells. Recent studies have shown that germline HLA gene zygosity, supertype and individual HLA genotypes may be associated with immunotherapy (IO) outcomes. We aimed to evaluate whether germline HLA-A gene haplotype and zygosity is associated with response to IO.
Methods
Pts enrolled in phase 1 clinical trials in the Vall d´Hebron Institute of Oncology Early Drug Development Unit with available HLA-A testing were reviewed. Median progression free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.
Results
From 2021 to 2023 a total of 247 eligible pts were reviewed. Median age was 59y, 63% female, main types of tumor with positive HLA biomarker were colorectal/anal cancer 19% (47pts), gynecological tumors 14%(34pts); and breast cancer 14% (34pts). Alleles present at >5% samples: 02:01:01 25%, 01:01:01 11%, 03:01:01 11%, 24:02:01 9%, 29:02:01 8%. Twenty-five (10.20%) pts presented HLA-A homozygosis. Homozygosis occurred in the most common haplotypes: 02:01:01 (14pts), 01:01:01 (2pts), 03:01:01 (4pts%), 24:02:01 (2pts%) and 29:02:01 (2pts). Eighty-five (34.5%) pts received IO; main types of tumors that received IO were genitourinary tumors 67% (10pts), gynecological tumors 45% (16pts) and colorectal/anal tumors 27% (13pts). Pts treated with anti-PD1 were 17 (20%), anti-PDL1 17 (20%) and other combinations 20 (24%). Twelve patients (17%) had PR, and thirty eight (45%) SD. Overal PFS and OS was 6.1 months and 29.6 months respectively. Presence of 03:01:01 was associated with a higher likelihood of response. Six pts with HLA homozygosis received inmunotherapy, all of them achieved SD as best response (NS).
Conclusions
Prevalence of HLA 02:01:01 in our population is significantly lower than reported in other populations. Presence of Homozygoses was not significantly associated with lack of response to inmunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research has been funded by CaixaResearch Advanced Oncology Research Program supported by Fundació La Caixa, by the Comprehensive Program of Cancer Immunotherapy & Immunology II (CAIMI-II) supported by the BBVA Foundation (grant 53/2021).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
689P - DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
Presenter: Omkar Marathe
Session: Poster session 17
690P - Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study
Presenter: Manish R Patel
Session: Poster session 17
691P - Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors
Presenter: John Strickler
Session: Poster session 17
692P - First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors
Presenter: Wen wee Ma
Session: Poster session 17
693P - Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models
Presenter: Yongqiang Shan
Session: Poster session 17
694P - Full efficacy analysis of phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy in refractory solid tumors
Presenter: Petri Bono
Session: Poster session 17
695P - A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti–PD-1) in patients (pts) with solid tumors or lymphoma
Presenter: Elena Garralda
Session: Poster session 17
696P - SIM1811-03 (SIM0235), an anti-tumor necrosis factor receptor-2 (TNFR2) monoclonal antibody, in patients with advanced solid tumor and/or cutaneous T cell lymphomas (CTCL): Preliminary results from an on-going first-in-human phase I trial in China
Presenter: Furong Liu
Session: Poster session 17